US Patent Issued to KANGSTEM BIOTECH on March 31 for "Method for producing umbilcal cord blood-derived stem cell with enhanced efficacy" (South Korean Inventors)

ALEXANDRIA, Va., March 31 -- United States Patent no. 12,589,116, issued on March 31, was assigned to KANGSTEM BIOTECH Co. LTD. (Seoul, South Korea).

"Method for producing umbilcal cord blood-derived stem cell with enhanced efficacy" was invented by Mijin Kim (Gyeonggi-do, South Korea), Jong Chan Ahn (Gyeonggi-do, South Korea), Seunghee Lee (Seoul, South Korea), Kwang-Won Seo (Gyeonggi-do, South Korea) and Kyung-Sun Kang (Seoul, South Korea).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed is a method for producing a stem cell with enhanced efficacy, a stem cell produced thereby, and a method for treating a disease using the same.According to the present invention, sizes of stem cells may be reduced a...